Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: A prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial

The Lancet Respiratory Medicine

Volumn 1, Issue 6, 2013, Pages 445-452

  Young, Lisa R ^a   Lee, Hye Seung ^b   Inoue, Yoshikazu ^c   Moss, Joel ^d   Singer, Lianne G ^e   Strange, Charlie ^f   Nakata, Koh ^g   Barker, Alan F ^h   Chapman, Jeffrey T ⁱ   Brantly, Mark L ^j   Stocks, James M ^k   Brown, Kevin K ^l   Lynch, Joseph P ^m   Goldberg, Hilary J ⁿ   Downey, Gregory P ^l   Swigris, Jeffrey J ^l   Taveira DaSilva, Angelo M ^d   Krischer, Jeffrey P ^b   Trapnell, Bruce C ^o,p   McCormack, Francis X ^p  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

^j UNIVERSITY OF FLORIDA   (United States)

^k UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^l DEPARTMENT OF MEDICINE   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^o CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^p UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; OXYGEN; PLACEBO; RAPAMYCIN; VASCULOTROPIN D; ANTINEOPLASTIC ANTIBIOTIC; BIOLOGICAL MARKER; VEGFD PROTEIN, HUMAN;

ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LYMPHANGIOLEIOMYOMATOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; OXYGEN THERAPY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; TREATMENT DURATION; ADULT; AGED; BLOOD; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VITAL CAPACITY; YOUNG ADULT;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; BIOMARKERS; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG NEOPLASMS; LYMPHANGIOLEIOMYOMATOSIS; MIDDLE AGED; PROSPECTIVE STUDIES; SIROLIMUS; VASCULAR ENDOTHELIAL GROWTH FACTOR D; VITAL CAPACITY; YOUNG ADULT;

EID: 84881343915     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(13)70090-0     Document Type: Article

References (27)

1. Henske EP, McCormack FX Lymphangioleiomyomatosis-a wolf in sheep's clothing. J Clin Invest 2012, 122:3807-3816.
2. Crino PB, Nathanson KL, Henske EP The tuberous sclerosis complex. N Engl J Med 2006, 355:1345-1356.
3. McCormack FX Lymphangioleiomyomatosis: a clinical update. Chest 2008, 133:507-516.
4. McCormack FX, Travis WD, Colby TV, Henske EP, Moss J Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. Am J Respir Crit Care Med 2012, 186:1210-1212.
5. Karbowniczek M, Astrinidis A, Balsara BR, et al. Recurrent lymphangiomyomatosis after transplantation-genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med 2003, 167:976-982.
6. Kumasaka T, Seyama K, Mitani KS, et al. Lymphangiogenesis in lymphangioleiomyomatosis: its implication in the progression of lymphangioleiomyomatosis. Am J Surg Pathol 2004, 28:1007-1016.
7. Kumasaka T, Seyama K, Mitani K, et al. Lymphangiogenesis-mediated shedding of lymphangioleiomyomatosis cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis. Am J Surg Pathol 2005, 29:1356-1366.
8. Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001, 7:186-191.
9. Seyama K, Kumasaka T, Souma S, et al. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol 2006, 4:143-152.
10. Young LR, Vandyke R, Gulleman PM, et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest 2010, 138:674-681.
11. Glasgow CG, Avila NA, Lin JP, Stylianou MP, Moss J Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest 2009, 135:1293-1300.
12. Chang WY, Cane JL, Blakey JD, Kumaran M, Pointon KS, Johnson SR Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis. Resp Res 2012, 13:34.
13. Young LR, Inoue Y, McCormack FX Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med 2008, 358:199-200.
14. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008, 358:140-151.
15. Dabora SL, Franz DN, Ashwal S, et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF-D levels decrease. PLoS One 2011, 6:e23379.
16. Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013, 381:817-824.
17. Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013, 381:125-132.
18. McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011, 364:1595-1606.
19. Davies DM, Johnson SR, Tattersfield AE, et al. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med 2008, 358:200-203.
20. Davies DM, de Vries PJ, Johnson SR, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res 2011, 17:4071-4081.
21. Young L, Inoue Y, Moss J, et al. Baseline serum VEGF-D levels are associated with disease severity and treatment response in lymphangioleiomyomatosis. Am J Respir Crit Care Med 2011, 183:A6351.
22. Spilke J, Piepho HP, Hu XY A simulation study on tests of hypotheses and confidence intervals for fixed effects in mixed models for blocked experiments with missing data. J Agr Biol Envir St 2005, 10:374-389.
23. Swigris JJ, Lee HS, Cohen M, et al. St George's respiratory questionnaire has longitudinal construct validity in lymphangioleiomyomatosis*. Chest 2013, published online Jan 17. 10.1378/chest.12-0161.
24. Taveira-DaSilva AM, Hedin C, Stylianou MP, et al. Reversible airflow obstruction, proliferation of abnormal smooth muscle cells, and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis. Am J Respir Crit Care Med 2001, 164:1072-1076.
25. Xu KF, Zhang P, Tian X, et al. The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (lymphangioleiomyomatosis). Respir Med 2013, 107:263-268.
26. Donohue JF Minimal clinically important differences in COPD lung function. COPD 2005, 2:111-124.
27. Ryu JH, Moss J, Beck GJ, et al. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 2006, 173:105-111.